ArticleScientific reports2026
Multi-epitope vaccine against nucleoprotein and envelopment polyprotein of Batai orthobunyavirus using molecular docking and molecular dynamics studies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Structure-Guided Immunoinformatics for the Rational Design of a Multi-Epitope Vaccine Against Batai Orthobunyavirus.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Immunoinformatics-driven design of a multi-epitope vaccine against Seoul Virus: Structural, dynamic, and immunogenic profiling.Clinics (Sao Paulo, Brazil) · 2026Article
- Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Batai orthobunyavirus (BATV) is a mosquito-borne orthobunyavirus that affects both humans and animals, and currently no licensed vaccine is available. The aim of this study was to design a multi-epitope vaccine candidate against BATV using a computational vaccinology pipeline. Predicted B-cell and T-cell epitopes from the nucleoprotein and envelopment polyprotein were selected and assembled into a single construct using an adjuvant and suitable linkers. The final construct comprised 247 amino acids and was predicted to be antigenic with an antigenicity score of 0.7676, non-allergenic, and non-toxic. Population coverage analysis showed a global coverage of 97.2%. Physicochemical evaluation indicated a theoretical pI of 10, instability index of 23.18, aliphatic index of 78.66, and GRAVY value of - 0.252, suggesting a stable and hydrophilic profile. Molecular docking with TLR3 produced a docking score of - 1418.9, suggesting a favorable interaction. Molecular dynamics simulations for 100 ns further indicated the stability of the vaccine-TLR3 complex. Immune simulation predicted the ability of the construct to stimulate immune responses in silico, and in silico cloning analysis supported its expression feasibility. Overall, these findings suggest that the proposed multi-epitope construct has promising predicted immunological and structural properties; however, experimental validation is required to confirm its immunogenicity and protective efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.